Research

Hormonal

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (exceeding 20% body weight in some cases) and improves glycemic control in patients with type 2 diabetes and obesity.

Tirzepatide is a weekly injection that mimics gut hormones to significantly reduce weight (often >20%) and improve blood sugar. It works best when paired with diet and exercise. Start with lower doses to minimize stomach issues like nausea, which usually improve over time.

GoodSupportsHIGH confidence
Os ensaios clínicos revisados demonstram que a Tirzepatida, um agonista duplo dos receptores GLP-1 e GIP, não apenas melhora o controle glicêmico em pacientes com diabetes tipo 2, mas também promove uma redução de peso considerável, com perdas superiores a 20% do peso corporal em alguns casos.
Vinicius Camilo Gomes dos Ramos et al. · Revista interdisciplinar em saúde · 2024

Why this rating

Based on an integrative review of 10 studies including phase 3 trials (SURPASS, SURMOUNT), though not a single primary RCT itself.

Source

O USO DE TIRZEPATIDA NO COMBATE A OBESIDADE: UMA ANÁLISE DOS BENEFÍCIOS E EFEITOS ADVERSOS

Vinicius Camilo Gomes dos Ramos et al. · Revista interdisciplinar em saúde · 2024

DOI 10.35621/23587490.v11.n1.p500-515

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →